HCPLive Network

Kynamro Approved for Genetic Condition Tied to Cholesterol

 
WEDNESDAY, Jan. 30 (HealthDay News) -- Kynamro (mipomersen sodium) has been approved by the U.S. Food and Drug Administration to treat homozygous familial hypercholesterolemia (HoFH), a rare inherited condition in which the body can't remove low-density lipoprotein (LDL) cholesterol from the blood, as an addition to lipid-lowering medications and diet.

Many people with HoFH have a heart attack and die before age 30, the FDA said in a news release. HoFH affects approximately one in every one million people in the United States. Kynamro is a once-weekly injection designed to lower creation of blood lipid particles that ultimately form LDL, the agency said.

The drug was clinically evaluated among 51 people with HoFH. Among Kynamro users, LDL levels fell an average of about 25 percent during the first 26 weeks, the FDA said. The drug will carry a "black box" label warning of possible liver abnormalities that could lead to progressive liver disease.

More common side effects noted during clinical testing included injection-site reactions, flu-like symptoms, nausea, headache, and elevated liver enzymes.

Kynamro is produced by Genzyme Corp., of Cambridge, Mass.
 

More Information


Copyright © 2013 HealthDay. All rights reserved.
 
 

Further Reading
Why do some allergic reactions produce only relatively mild symptoms while others trigger anaphylaxis and eventual death?
Obesity in children is a very complex problem. How children eat and what they believe about food and obesity is largely determined in their family units.
Kidney donors may have lower 1,25-dihydroxyvitamin D and phosphate levels. Their parathyroid hormone levels may be elevated, but with minimal effect on calcium levels.
More Reading